| Title | Author(s) | Issue date | ???itemlist.??? |
| Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study | Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H.; Pavlidis, N.; Verweij, J.; Sessa, C.; Kaye, S.; Roelvink, M.; Wanders, J.; Hanauske, A. | 24-Nov-2015 | - |
| Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG) | Chollet, P.; Schoffski, P.; Weigang-Kohler, K.; Schellens, J. H.; Cure, H.; Pavlidis, N.; Grunwald, V.; De Boer, R.; Wanders, J.; Fumoleau, P. | 24-Nov-2015 | - |
| Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies | Schellens, J. H.; Heinrich, B.; Lehnert, M.; Gore, M. E.; Kaye, S. B.; Dombernowsky, P.; Paridaens, R.; van Oosterom, A. T.; Verweij, J.; Loos, W. J.; Calvert, H.; Pavlidis, N.; Cortes-Funes, H.; Wanders, J.; Roelvink, M.; Sessa, C.; Selinger, K.; Wissel, P. S.; Gamucci, T.; Hanauske, A. R. | 24-Nov-2015 | - |
| Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9 | Schellens, J. H.; Dombernowsky, P.; Cassidy, J.; Epelbaum, R.; Dirix, L.; Cox, E. H.; Wanders, J.; Calabresi, F.; Paridaens, R.; Monfardini, S.; Wolff, J.; Loos, W. J.; Verweij, J.; Pavlidis, N.; Hanauske, A. R. | 24-Nov-2015 | - |
| Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG | Joerger, M.; Huitema, A. D.; Richel, D. J.; Dittrich, C.; Pavlidis, N.; Briasoulis, E.; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Fety, R.; de Bruijn, E.; Hempel, G.; Karlsson, M.; Tranchand, B.; Schrijvers, A. H.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. | 24-Nov-2015 | - |
| Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group | Joerger, M.; Huitema, A. D.; Richel, D. J.; Dittrich, C.; Pavlidis, N.; Briasoulis, E.; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Calvert, H.; Boddy, A. V.; Hollema, H.; Fety, R.; Van der Vijgh, W. J.; Hempel, G.; Chatelut, E.; Karlsson, M.; Wilkins, J.; Tranchand, B.; Schrijvers, A. H.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. | 24-Nov-2015 | - |
